Study S001816

Does the Hematopoietic Stem Cell Govern Residual Inflammatory Cardiovascular Risk in Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05597202
Acronym: DOTAFLAME
Study type: INTERVENTIONAL
Phase: PHASE4
Masking: NONE
Status: UNKNOWN
Enrollment: 22
Start: 2023-01-01
Primary completion: 2024-03
Lead sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Conditions: Type 2 Diabetes
Interventions: DRUG:Semaglutide, 2.0 mg/mL
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Difference in coronary 68Ga-Dotatate uptake after treatment. [6 months]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.